Ed Arce
Stock Analyst at HC Wainwright & Co.
(3.80)
# 657
Out of 4,896 analysts
486
Total ratings
42.69%
Success rate
10.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVTX Travere Therapeutics | Assumes: Buy | $30 | $16.46 | +82.26% | 21 | Jun 11, 2025 | |
| MTVA MetaVia | Reiterates: Buy | $12 | $0.72 | +1,571.31% | 3 | Apr 16, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $75 | $5.01 | +1,397.01% | 27 | Apr 11, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $13.78 | +335.41% | 31 | Apr 10, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $3.93 | +90.84% | 36 | Apr 4, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $3.35 | +288.18% | 16 | Apr 2, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Neutral | n/a | $2.51 | - | 17 | Apr 2, 2025 | |
| TLPH Talphera | Reiterates: Buy | $6 | $0.52 | +1,053.85% | 6 | Apr 1, 2025 | |
| ALGS Aligos Therapeutics | Reiterates: Buy | $70 | $8.36 | +737.32% | 6 | Mar 31, 2025 | |
| DRRX DURECT | Reiterates: Neutral | n/a | $0.63 | - | 13 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $18.75 | - | 8 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $0.47 | +2,437.00% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.41 | - | 24 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $9.47 | +237.91% | 11 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $35 | $50.54 | -30.74% | 22 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $75 | $51.54 | +45.52% | 25 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $29 → $21 | $11.00 | +90.91% | 22 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $52.66 | +36.73% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $315.20 | +28.49% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $4.49 | +22.49% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $29.51 | +221.92% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $6.56 | +174.39% | 11 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $3.65 | +256.16% | 18 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $3.17 | +57.73% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $21.54 | +122.84% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $4.90 | +53.06% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.13 | +342.48% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $8.80 | +47.73% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 → $240 | $0.59 | +40,577.97% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.21 | - | 8 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $23.82 | +4.95% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.94 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $25.00 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $31.11 | -77.50% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $32.52 | -35.42% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.70 | - | 2 | Feb 15, 2017 |
Travere Therapeutics
Jun 11, 2025
Assumes: Buy
Price Target: $30
Current: $16.46
Upside: +82.26%
MetaVia
Apr 16, 2025
Reiterates: Buy
Price Target: $12
Current: $0.72
Upside: +1,571.31%
Unicycive Therapeutics
Apr 11, 2025
Reiterates: Buy
Price Target: $75
Current: $5.01
Upside: +1,397.01%
Arcturus Therapeutics Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $60
Current: $13.78
Upside: +335.41%
Akebia Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $7.5
Current: $3.93
Upside: +90.84%
Inventiva
Apr 2, 2025
Reiterates: Buy
Price Target: $13
Current: $3.35
Upside: +288.18%
Galectin Therapeutics
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $2.51
Upside: -
Talphera
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $0.52
Upside: +1,053.85%
Aligos Therapeutics
Mar 31, 2025
Reiterates: Buy
Price Target: $70
Current: $8.36
Upside: +737.32%
DURECT
Mar 27, 2025
Reiterates: Neutral
Price Target: n/a
Current: $0.63
Upside: -
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $18.75
Upside: -
Mar 19, 2025
Reiterates: Buy
Price Target: $12
Current: $0.47
Upside: +2,437.00%
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.41
Upside: -
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $9.47
Upside: +237.91%
Mar 10, 2025
Maintains: Buy
Price Target: $24 → $35
Current: $50.54
Upside: -30.74%
Mar 3, 2025
Maintains: Buy
Price Target: $72 → $75
Current: $51.54
Upside: +45.52%
Feb 28, 2025
Reiterates: Buy
Price Target: $29 → $21
Current: $11.00
Upside: +90.91%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $52.66
Upside: +36.73%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $315.20
Upside: +28.49%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $4.49
Upside: +22.49%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $29.51
Upside: +221.92%
Feb 11, 2025
Reiterates: Buy
Price Target: $18
Current: $6.56
Upside: +174.39%
Feb 7, 2025
Reiterates: Buy
Price Target: $13
Current: $3.65
Upside: +256.16%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $3.17
Upside: +57.73%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $21.54
Upside: +122.84%
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $4.90
Upside: +53.06%
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $1.13
Upside: +342.48%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $8.80
Upside: +47.73%
Mar 26, 2024
Reiterates: Buy
Price Target: $12 → $240
Current: $0.59
Upside: +40,577.97%
Mar 20, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.21
Upside: -
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $23.82
Upside: +4.95%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.94
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $25.00
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $31.11
Upside: -77.50%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $32.52
Upside: -35.42%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.70
Upside: -